Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-08-17), Eckert & Ziegler SE's 1-Year Sharpe Ratio is -2.02.
Eckert & Ziegler SE (CHIX:EUZd) 1-Year Sharpe Ratio Explanation
The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.
The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.
Eckert & Ziegler SE 1-Year Sharpe Ratio Related Terms
CHIX:EUZD vs ABT, SYK, MDT: 1-Year Sharpe Ratio Comparison
For the Medical Devices subindustry, Eckert & Ziegler SE's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eckert & Ziegler SE 1-Year Sharpe Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Eckert & Ziegler SE's 1-Year Sharpe Ratio distribution charts can be found below:
* The bar in red indicates where Eckert & Ziegler SE's 1-Year Sharpe Ratio falls into.
Eckert & Ziegler SE 1-Year Sharpe Ratio Calculation
The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.
Eckert & Ziegler SE (CHIX:EUZD) has a 1-Year Sharpe Ratio of -2.02 as of Aug. 17, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Eckert & Ziegler SE and its competitors.
Is Eckert & Ziegler SE's 1-Year Sharpe Ratio too high?
Eckert & Ziegler SE's current 1-Year Sharpe Ratio is -2.02. Overall, Eckert & Ziegler SE has a GF Score™ of 93/100, reflecting its overall financial health beyond just this single metric.
How does Eckert & Ziegler SE's 1-Year Sharpe Ratio compare to ABT and SYK?
Eckert & Ziegler SE's 1-Year Sharpe Ratio of -2.02 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Medical Devices & Instruments company?
A good 1-Year Sharpe Ratio depends on the Medical Devices & Instruments industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Eckert & Ziegler SE and its competitors. Eckert & Ziegler SE's current 1-Year Sharpe Ratio is -2.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eckert & Ziegler SE stock overvalued right now?
Eckert & Ziegler SE (CHIX:EUZD) has a current 1-Year Sharpe Ratio of -2.02. The stock's GF Value™ is €18.17, compared to a current price of €15.19 — trading 16.4% below its estimated fair value. The current 1-Year Sharpe Ratio is -2.02. Eckert & Ziegler SE's overall GF Score™ is 93/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Eckert & Ziegler SE (CHIX:EUZD), the current 1-Year Sharpe Ratio is -2.02 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eckert & Ziegler SE (CHIX:EUZD) Overvalued in 2026?
Based on GuruFocus' analysis, Eckert & Ziegler SE stock appears to be undervalued.
The current stock price of €15.19 is trading 16.4% below its estimated GF Value™ of €18.17.
Key valuation signals for CHIX:EUZD:
1-Year Sharpe Ratio: -2.02
GF Value™: €18.17 vs. price of €15.19 (16.4% below fair value)
No single metric tells the full story. See the CHIX:EUZD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eckert & Ziegler SE is a holding company with specialised in the processing of radioisotopes and the development, production and sale of isotope technology components, radiopharmaceuticals and related products. It is an international manufacturer of isotope technology components for medical, scientific, and industrial applications. The group's products are mainly used in cancer therapy, nuclear imaging, and industrial metrology. The company's segments are Medical, Isotope Products, and Other. The majority of revenue comes from Medical segment which provides pharmaceutical-quality radioactive ingredients and markets products for the treatment and diagnosis of cancers. Geographically, the company generates a majority of its revenue from Europe and then North America, Asia/Pacific, and other.
93GF Score
Get the complete analysis for CHIX:EUZD
1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:EUZD has been successfully added to your 
